High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-05-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-3020PMID 23658460PMCID PMC3959126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

  2012cited by this paper
• International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

  2012cited by this paper
• Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience

  2012cited by this paper
• Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

  2012cited by this paper
• High BRCA 1/2 Mutation Rate With Less Significant Breast Cancer Among Families With Pancreatic Cancer Predisposition: A New Indication for BRCA 1/2 Testing?

  2011cited by this paper
• German national case collection for familial pancreatic cancer (FaPaCa): ten years experience

  2011cited by this paper
• Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.

  2011cited by this paper
• Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation

  2011cited by this paper
• Risk of Pancreatic Cancer in Families With Lynch Syndrome

  2011cited by this paper
• Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.

  2011cited by this paper
• Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

  2011cited by this paper
• Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer Families

  2011cited by this paper
• Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics

  2010cited by this paper
• Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

  2010cited by this paper
• Head and neck squamous cell carcinoma in FAMMM syndrome

  2009cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009cited by this paper
• BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.

  2009influential reference
• Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

  2009cited by this paper
• The Yield of First-Time Endoscopic Ultrasonography in Screening Individuals at a High Risk of Developing Pancreatic Cancer

  2009cited by this paper
• Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer

  2009cited by this paper
• Risk of pancreatic cancer in families with Lynch syndrome.

  2009cited by this paper
• Germline BRCA1 mutations predispose to pancreatic adenocarcinoma

  2008cited by this paper
• The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer

  2007cited by this paper
• Advances in counselling and surveillance of patients at risk for pancreatic cancer

  2007cited by this paper
• Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• Cancer Facts & Figures 2004

  2004cited by this paper
• Familial melanoma, pancreatic cancer and germline CDKN2A mutations

  2004cited by this paper
• Breast cancer genetics in African Americans

  2003cited by this paper
• BRCA2 germline mutations in familial pancreatic carcinoma.

  2003cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.

  2002cited by this paper
• Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2

  2002cited by this paper
• Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

  2002cited by this paper
• Familial pancreatic cancer.

  2001cited by this paper
• The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel

  2001cited by this paper
• Very high risk of cancer in familial Peutz-Jeghers syndrome.

  2000cited by this paper
• Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

  2000influential reference
• BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.

  2000cited by this paper
• Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.

  2000cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Early Diagnosis and Treatment of Pancreatic Dysplasia in Patients with a Family History of Pancreatic Cancer

  1999cited by this paper
• Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium

  1999cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group.

  1997cited by this paper
• Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients

  1997cited by this paper
• Population genetics of BRCA1 and BRCA2.

  1997cited by this paper
• Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

  1996cited by this paper
• Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

  1996cited by this paper
• The genetic attributable risk of breast and ovarian cancer

  1996cited by this paper
• Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study.

  1985cited by this paper
• Familial pancreatic cancer.

  1983cited by this paper

• Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects

  2025cites this paper
• Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: An opportunity not to be missed.

  2024cites this paper
• Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application

  2024cites this paper
• From precursor to cancer: decoding the intrinsic and extrinsic pathways of pancreatic intraepithelial neoplasia progression.

  2024cites this paper
• Becker Digital Commons

  2023cites this paper
• Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

  2023cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals.

  2022cites this paper
• Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes

  2022cites this paper
• BRCA mutated pancreatic cancer: A change is coming

  2021cites this paper
• Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing

  2021cites this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Targeting DNA damage repair pathways in pancreas cancer

  2021cites this paper
• A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer

  2021cites this paper
• NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

  2020cites this paper
• Poly(ADP‐ribose) polymerase inhibition in pancreatic cancer

  2020cites this paper
• The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

  2020cites this paper
• Frequency of pathogenic/likely pathogenic germline variants in cancer‐related genes among children with acute leukemia in Saudi Arabia

  2020cites this paper
• Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies

  2020cites this paper
• Metabolic Alterations in Pancreatic Cancer Progression

  2019cites this paper
• Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

  2019cites this paper
• Human Mutation

  2019cites this paper
• Talking Genes in Breast and Pancreatic Malignancies

  2019cites this paper
• Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.

  2019cites this paper
• Морфологические особенности BRCA1‑ассоциированных опухолей

  2018cites this paper
• Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway

  2018cites this paper
• Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

  2018cites this paper
• Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy

  2018cites this paper
• Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?

  2018cites this paper
• Clinical significance of pancreatic intraepithelial neoplasia in resectable pancreatic cancer on survivals

  2018cites this paper
• Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

  2018cites this paper
• Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts

  2018cites this paper
• Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.

  2018cites this paper
• Population masculine au sein des familles avec mutation germinale dans les gènes BRCA1 et BRCA2 aspects cliniques et pathologiques des cancers

  2018influential citation
• Characteristics and Clinical Outcomes of Individuals at High Risk for Pancreatic Cancer: A Descriptive Analysis from a Comprehensive Cancer Center

  2018cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.

  2017cites this paper
• Germline mutations in pancreatic cancer and potential new therapeutic options

  2017cites this paper
• Investigation into the relationship between PARPs in DNA repair and synthetic lethality with homologous recombination deficiency

  2017cites this paper
• Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program

  2017cites this paper
• Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer.

  2016cites this paper
• Neoadjuvant treatment for resectable pancreatic adenocarcinoma.

  2016cites this paper
• Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b

  2016influential citation
• Diagnosis and Management of Hereditary Pancreatic Cancer.

  2016cites this paper
• Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

  2016cites this paper
• The c.*229C > T gene polymorphism in 3′UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma

  2016cites this paper
• Pancreatic ductal adenocarcinoma in BRCA 2 mutation carriers

  2016cites this paper
• Pankreaskarzinom

  2016cites this paper
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

  2016cites this paper
• “Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

  2016cites this paper
• Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor

  2016cites this paper
• Pancreatic cancer: BRCA mutation and personalized treatment

  2015cites this paper
• Biomarkers for personalized medicine in GI cancers.

  2015cites this paper
• Molecular Pathology of Pancreatic Adenocarcinoma : A Review

  2015cites this paper
• Loss of heterozygosity at the calcium regulation gene locus on chromosome 10q in human pancreatic cancer.

  2015cites this paper
• Hereditary Pancreatic Cancer Syndromes.

  2015cites this paper
• Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

  2015cites this paper
• Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

  2015cites this paper
• Résistance aux inhibiteurs de PARP

  2015cites this paper
• Germline Mutations in Predisposition Genes in Pediatric Cancer.

  2015cites this paper
• Zane Simtniece PROGNOSTIC FACTORS OF SURGICALLY TREATED PANCREATIC CANCER Summary of the Doctoral Thesis for obtaining the degree of a Doctor of Medicine Speciality – Pathology

  2015cites this paper
• Neoplasia of the gastrointestinal tract

  2015cites this paper
• Absence of Pancreatic Intraepithelial Neoplasia Predicts Poor Survival After Resection of Pancreatic Cancer

  2014cites this paper
• BRCA1 and BRCA2 Cancer Syndromes and Clinical Significance

  2014cites this paper
• PARP-inhibitors in BRCA-associated pancreatic cancer.

  2014cites this paper
• Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2

  2014cites this paper
• Pathology, genetic alterations, and targets of differentially expressed microRNAs in pancreatic cancer

  2014cites this paper
• The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.

  2014cites this paper
• BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high‐risk pancreatic cancer screening and pancreatic cancer cohorts

  2014cites this paper
• Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

  2014cites this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cites this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cites this paper
• Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.

  2014cites this paper
• Incidence and trends of malignant and benign pancreatic lesions in Yazd, Iran between 2001 and 2011.

  2013cites this paper